748 Results

Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available?

Summary: The present study reviews the current definition of advanced cSCC and discusses the new systemic approaches, including checkpoint inhibitors.

Systemic Immunotherapy for Advanced Cutaneous Squamous Cell Carcinoma.

Advanced (i.e., unresectable) cutaneous squamous cell carcinoma (cSCC) is a rare condition with a dismal prognosis. Although less than 5% of cSCC patients develop metastases or local recurrence after...

Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.

Cutaneous squamous cell carcinoma (cSCC) is the second most frequent type of malignancy in Caucasians worldwide. Several factors have been correlated with aggressiveness and likelihood of recurrence...

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

Background: Combined BRAF-MEK inhibitor therapy is the standard of care for BRAF V600-mutant advanced melanoma. We investigated encorafenib, a BRAF inhibitor with unique target-binding properties...

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.

Background: Dual inhibition of the mitogen-activated protein kinase pathway with BRAF/MEK inhibitor (BRAFi/MEKi) therapy is a standard treatment for BRAFV600-mutant metastatic melanoma and has...

Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.

Areas covered: Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK inhibitor combinations.

Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy.

Major advances in the understanding of the pathophysiology of melanoma have led to a new era of melanoma treatment with targeted therapy and immunotherapies. Since 2011, four new classes of medications...

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.

Background: Psoriasis is an autoimmune disease that affects approximately 100 million people worldwide, and is a disease that can be ameliorated by anti-cytokine treatment. We aimed to compare the efficacy and safety of...

Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis.

Psoriasis, an inflammatory skin disease, and psoriatic arthritis (PsA), an inflammatory arthritis, share clinical, genetic, and pathogenic factors and may be summed as one disease, the psoriatic disease.

Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.

Aim: Gordon et al. investigated the efficacy and safety of risankizumab [an anti‐interleukin (IL)‐23p19 biologic] compared with ustekinumab (anti‐IL‐12/23p40) and placebo in patients with moderate‐to‐severe chronic plaque psoriasis.

Load more